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Abstract 
Background: Cognitive behavioral therapy (CBT) may be useful for improving the health-
related quality of life (HRQOL) of at least some inflammatory bowel disease (IBD) patients, 
especially those with psychiatric comorbidities. However, CBT can be difficult to access. 
These difficulties can be overcome by computerized CBT (CCBT). This is a randomized 
controlled trial of a self-administered CCBT intervention for IBD patients focused on 
improving HRQOL. It is hypothesized that CCBT completers will have an improved HRQOL 
relative to people not allocated to the CCBT.  
Methods: IBD patients were randomly allocated to CCBT (n = 113) versus treatment as 
usual (TAU; n = 86). The IBD questionnaire (IBDQ) at twelve weeks after baseline was the 
primary outcome while generic HRQOL, anxiety, depression, coping strategies, perceived 
stress, and IBD symptoms were secondary outcomes. Outcomes were also measured at six 
months after baseline. Predictors of dropout were also determined. 
Results: Twenty-nine CCBT participants (25.7%) completed the CCBT. IBDQ was 
significantly increased at twelve weeks in CCBT completers compared to TAU patients (F = 
6.38, p = 0.01). SF-12 mental (F = 5.00, p = 0.03) was also significantly better in CCBT 
compared to TAU patients at twelve weeks. These outcomes were not maintained at six 
months. The predictors of dropout were baseline depression, biological use, lower IBDQ 
scores, and not having steroids. 
Conclusion: Improvements at twelve weeks after baseline were not maintained at six 
months. Future research should aim to improve adherence rates. Moreover, CCBT may not 
work for IBD patients with comorbid depression. 
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Introduction 
Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative 
colitis (UC), is a chronic relapsing-remitting condition with a range of symptoms including 
diarrhea, rectal bleeding, abdominal pain, and extra-intestinal symptoms (e.g., arthritis, liver 
symptoms, skin and eye manifestations) 
1
. IBD patients suffer from an impaired health-
related quality of life (HRQOL) 
2, 3
 and have an increased susceptibility to anxiety and 
depression 
2, 4
. 
Psychotherapy, especially cognitive behavioral therapy (CBT) where people are taught to 
identify and modify unhelpful thinking styles and maladaptive behaviors 
5-7
, may be a useful 
intervention for at least some IBD patients, especially those with psychiatric comorbidities 
2, 
8, 9
. CBT is based on the premise that altering maladaptive thoughts results in changes in both 
emotions and behavior
10
. Psychotherapy may improve HRQOL 
11, 12
 for IBD patients but not 
all studies have reported psychotherapy to improve HRQOL 
13, 14
. However, these studies 
were highly heterogeneous in terms of interventions, study populations, and measures of 
HRQOL which will have contributed to the inconsistent findings. The one study to have used 
CBT and have HRQOL as an outcome variable showed the intervention to improve 
inflammatory bowel disease questionnaire (IBDQ) scores compared to treatment as usual 
(TAU) 
15
. There are barriers to the implementation of psychotherapy, such as time and travel 
burden for patients to attend face-to-face sessions, shortages of adequately trained therapists, 
high costs, potential stigma associated with seeking professional help and lack of 
accessibility in remote areas 
16-19
. These limitations may be overcome by the utilization of 
computerized interventions like computerized CBT (CCBT), which is CBT that is self-
directed (i.e. not facilitated by a therapist) and implemented via a computer 
20, 21
. 
When asked to choose between psychological interventions, a majority of IBD patients 
expressed a preference for a computerized over face-to-face intervention 
22
. Ehealth 
interventions (broadly defined) have shown promise in terms of improving HRQOL in 
gastrointestinal conditions 
23
. Computerized psychotherapy may be as effective as traditional 
psychotherapy 
24
. 
There are a number of different mechanisms by which CCBT can have its effect on HRQOL, 
anxiety, and depression. These include improved coping strategies, and decreased perceived 
stress and IBD symptoms. Coping strategies, which are specific methods for responding to 
stressors, can be adaptive (i.e. improve outcomes) or maladaptive (i.e. worsen outcomes) 
25
; 
CCBT should aim to increase adaptive and decrease maladaptive coping strategies. Perceived 
stress measures the extent to which people appraise situations or events as “unpredictable, 
uncontrollable, and overloading” 26; CCBT should ultimately lead to decreased perceived 
stress through improving the participant’s response to stress. Finally, IBD symptoms are the 
strictly physical manifestations of IBD as measured by brief IBD symptom questionnaires
27, 
28
; a cognitive behavioral approach may improve symptoms in IBD patients 
15
. 
This paper describes a randomized controlled trial (RCT) of a self-administered CCBT 
intervention for IBD patients focused on improving HRQOL via better management of stress 
and improved coping with IBD. The comparison condition is TAU which is normal medical 
treatment. It is hypothesized that CCBT completers will have an improved HRQOL, anxiety, 
depression, coping strategies, perceived stress, and IBD symptoms relative to people not 
allocated to the CCBT.  
Materials and Methods 
Trial design 
This study was a multicenter (i.e. Christchurch, West Coast, and Nelson) RCT of CCBT in 
addition to usual therapy in adults with IBD, with parallel groups, without blinding and with 
imbalanced randomization. No changes to the trial design occurred during the course of the 
study.  
Participants 
Inclusion/Exclusion Criteria 
Eligible patients were all adults with IBD aged 18-65, computer literate, and had access to a 
computer and the internet. Participants were excluded if their disease was too severe (e.g., 
recent major surgery and/or complicated disease). Participants had to (a) have sufficient 
knowledge of English to answer the questionnaires and participate in the intervention and (b) 
be willing to participate in the intervention and answer the questionnaires at baseline, post-
intervention (twelve weeks after baseline) and six months after baseline. Patients who had an 
existing psychotic disorder or were currently receiving any form of psychological 
intervention (i.e. presently receiving CBT or another therapy from a psychologist or 
counsellor), or were alcohol or substance dependent were excluded. Those with an ileostomy 
or colostomy were excluded from the study because the primary outcome measure, namely 
IBDQ, is not designed for those with an ileostomy or colostomy. 
Recruitment Methods and Study Settings 
Participants were recruited via five different sources from 29 October, 2012 until 2 October, 
2013: Christchurch Hospital Gastroenterology Outpatient Clinic; Greymouth Hospital 
Outpatient Clinic; Nelson Crohn’s and Colitis Support Group; Christchurch 
Gastroenterologists’ private clinics; and an existing database from two previous observational 
studies 
22, 29
 which were unrelated to this RCT. 
Most study participants were recruited from Christchurch, New Zealand. If they were 
interested and eligible, they were approached by the principle investigator and given an 
information sheet and consent form. Those who opted out were not contacted further and 
those who did not respond within four weeks were contacted up to three times via two 
different methods (phone, text message, email or letter).  
Interventions 
After their consent was obtained, participants were randomized to CCBT or TAU. Those who 
were allocated to the CCBT group were shown how to login and use the CCBT website; they 
received a username and password. Once the induction was completed, all participants in 
both groups were sent a link to the questionnaires via email. All patients in the TAU group 
were aware of the CCBT patients receiving the CCBT (i.e. no blinding). 
Those in the CCBT group received self-administered CCBT in addition to TAU. Those in the 
TAU group received only usual IBD treatment which is treatment from their physician 
exactly as they had received previous to the study; they were not referred for mental health 
intervention. Both groups completed questionnaires at baseline, twelve weeks after baseline, 
and six months after baseline. The CCBT was implemented using MedMoodle 
30
. The CCBT 
involved eight sessions with sixty-two resources (see Supplementary Table 1 for details of 
each session). The sessions briefly addressed dealing with stress through relaxation, how 
thoughts influence feelings and behavior, avoidance, coping, effective communication and 
attention and distraction for dealing with pain. They were designed based on the existing 
CBT program for IBD (http://www.tameyourgut.com) which adapted classic CBT activities 
to address the specific needs of IBD patients (e.g. toilet dependence, open communication 
about bowel problems, dealing with abdominal pain) but abbreviated the original 10-week 
program to 8 weeks to reduce participant burden (the specific program is available via the 
corresponding author upon request). The activities were designed based on the classic CBT 
model developed by Beck 
5-7
. All participants were expected to complete activities in each 
session (i.e. there was no matching between participant exact problem and the activities as the 
therapy was not individualized). The program was focused on improving HRQOL via better 
management of stress, fixing underlying maladaptive thoughts, and improved coping with 
IBD. 
Outcomes 
The timing of all assessments is shown in Supplementary Table 2. Outcomes were assessed 
by validated questionnaires as described below.  
Primary 
The primary outcome was IBD-specific HRQOL at twelve weeks as assessed by the IBDQ 
31
, 
which contains thirty-two items divided in to four health sub-dimensions: bowel symptoms 
(e.g., loose stools, abdominal pain; ten items), systemic symptoms (e.g., fatigue, sleeping 
problems; five items), social functioning (e.g., limited social activity, school or work 
attendance; five items), and emotional functioning (e.g., irritability, anger, depression; twelve 
items). Responses are scored on a seven point Likert scale where higher scores indicate a 
better HRQOL. The IBDQ is reliable and valid 
32
, has a range of 32 to 224
33
, and has a 
minimum clinically significant change score of twenty points
34
. 
Secondary 
Generic HRQOL was measured with the Short Form 12 (SF-12) and contains twelve 
questions 
35
. Answers are scored and totaled to produce raw scale scores for a mental and 
physical subscale which are then transformed to a 0 – 100 scale 36. These scores have a mean 
of fifty and standard deviation (SD) of ten 
37
.  
Anxiety and depression were assessed with the Hospital Anxiety and Depression Scale 
(HADS) 
38
 . It is designed to be used in a hospital context as it omits questions related to 
symptoms that may be caused by physical illness (e.g. dizziness) concentrating on 
psychological aspects of anxiety and depression. Sensitivity and specificity are optimum 
when caseness is defined at eight or above for the anxiety and depression subscales 
39
. The 
HADS has been used extensively in IBD studies 
40-42
.  
Stress was measured with the Perceived Stress Scale (PSS). This is the most commonly used 
measure of the perception of stress 
26
. There is a fourteen item, ten item and four item version 
26, 43
. The ten item version (PSS-10) was used for this study. The items are answered on a five 
point Likert scale with higher scores reflecting a greater extent to which situations in a 
person’s life are interpreted as being stressful 26, 43. Higher PSS scores have been associated 
with smoking status, colds, and other stress measures 
43
.  
Social functioning was measured with the Social Functioning Questionnaire (SFQ) which is 
an eight item questionnaire 
44
. The questions are answered on a scale of zero to three and a 
score of ten or more indicates poor social functioning 
44
.  
Neuroticism was measured with the Eysenck Personality Questionnaire–Brief Version (EPQ-
BV) which is used to measure extraversion and neuroticism
45
. This study omitted the 
extraversion subscale. 
The Brief Coping Operations Preference Enquiry (Brief COPE) was used to measure coping 
strategies 
46
. It is a validated twenty-eight item questionnaire used to assess coping behaviors 
known to be adaptive and maladaptive strategies. There are fourteen subscales with two items 
each. The coping strategies are adaptive problem-focused (use of instrument support, 
planning, and active coping), adaptive emotion-focused (use of emotional support, religion, 
positive reframing, acceptance, and humor), and maladaptive (behavioral disengagement, 
denial, self-distraction, self-blame, substance use, and venting) coping strategies 
47
. 
The Harvey Bradshaw Index (HBI) was used to measure IBD-related symptoms in CD 
patients 
27
 and the Simple Clinical Colitis Activity Index (SCCAI) was used to measure 
symptoms in UC and inflammatory bowel disease-unspecified patients 
28
. 
CCBT usage and acceptability 
Use of the program for each participant was measured by monitoring the number of logins 
and resources used by each participant. There were sixty-two resources available for 
download over eight sessions. People who downloaded half or more of the resources were 
considered to be “completers”. 
CCBT acceptability was determined using a ten item questionnaire designed by the authors. 
Questions were asked about participant enjoyment, the relevance of the program to them, 
whether it improved their understanding of IBD, whether it improved their psychological or 
physical health, and whether they would recommend such a program to others with 
gastrointestinal disorders. 
Sample size 
Power calculation was conducted on a per-protocol (PP), not intention-to-treat (ITT), basis. It 
was calculated that two hundred and thirty eight participants would need to be allocated at a 
ratio of nine-to-eight to the CCBT versus TAU group because more CCBT participants were 
expected to drop out from the study. This was based on 80% power (p-value 0.05) and the 
CCBT group (n = 126) having an IBDQ increase of twenty more points (which is the 
minimum clinical significance
34
) than the TAU group (n = 112).  
Randomization 
This study was an open label RCT with imbalanced randomization (9 CCBT: 8 TAU). 
Randomization to CCBT or TAU took place after screening and consent. An excel 
spreadsheet with 238 numbers randomly allocated to CCBT or TAU at a ratio of nine-to-eight 
was used and a number between one and 238 was produced by the website random.org 
48
. 
The participants were allocated in groups of six to nineteen (depending on how many were 
recruited in the fortnight). Allocation concealment was not used but participants were present 
when they were randomized so they could see how they were allocated to the CCBT or TAU 
group. 
Participant contact via email, text message, and phone call 
All participants (CCBT and TAU) were contacted via email to complete the questionnaires. 
They were text messaged if they did not complete the questionnaire and were then contacted 
via phone call if they still had not completed the questionnaire. 
In addition, participants in the CCBT group were emailed once per week for eight weeks to 
remind them of the availability of the program and that the next topic was released. CCBT 
participants were also text messaged at six weeks to encourage them to keep looking at the 
program and to contact the lead investigator if they had any questions. 
Statistical methods 
SPSS 22-x
49
 was used to perform the statistical analyses. There were two populations 
analyzed for the CCBT group. The first was the ITT population who were participants 
randomized into the trial; incomplete data was replaced by using last observation carried 
forward. The second was the PP population who were participants who completed the 
protocol (i.e. completed >50% of the resources) and completed the baseline and follow-up 
assessments.  
The primary outcome was the PP comparison of IBDQ change scores for CCBT completers 
versus TAU participants. Linear mixed effects models were performed for all variables with 
the change in the outcome as the dependent, CCBT completers versus TAU as the fixed 
factor and baseline outcome scores as the covariates. ITT analyses were performed last; only 
the primary outcome (IBDQ) and any measures which were significant in the PP analyses had 
ITT analyses performed. Attrition rates for the groups and the binary outcome of 
improvement of IBDQ score (improvers defined as change of >20 vs. non-improvers) were 
compared with the Fisher’s exact test (two tailed). 
Among CCBT participants, binary logistic regressions were performed to determine the 
predictors for completing the program (i.e. completing >50% of the resources); unadjusted 
odds ratios were calculated for each of the predictors before a multivariate model was built.  
Incomplete data 
All questions had a “Decline to answer” option which meant some questionnaires were not 
fully completed. When a subscale of a questionnaire had one answer or 10% or less of 
answers missing, missing or “Decline to answer” answers were replaced with means for the 
answers on the other questions for that subscale. In cases where more than one answer and 
more than 10% of answers for a questionnaire were omitted by a participant, the 
questionnaire was treated as missing for that participant. 
Ethical Considerations 
The study was conducted with the consent of the New Zealand Health and Disability Ethics 
Committee (12/NTA/46). Each participant provided informed consent and only de-identified 
data are presented. The study was registered with the Australian New Zealand Clinical Trials 
Registry (ACTRN12612000922875).  
Results 
Participant Flow 
The participant flow is shown in Figure 1. Of the 231 randomized participants, thirty-two 
patients were excluded after randomization as they did not complete the baseline 
questionnaire. One hundred of the CCBT participants (88.5%) logged in at least once and 
twenty-nine (25.7%) of CCBT participants were “completers”.  
Recruitment Issues 
Participants were recruited between 22 October, 2012 and 8 October, 2013. The first patient 
was recruited on 22 October, 2012 and the last patient had their six month follow up 
performed on 8 April, 2014. Recruitment was ceased short of the power calculation of 238 as 
it became apparent that the number of dropouts in the CCBT group had been significantly 
underestimated; it was expected 80% would complete the intervention but 26% did. 
Baseline data 
Baseline data for the CCBT and TAU groups are shown in Table 1 and Table 2. 
Attrition 
At baseline, 113 CCBT and eighty-six TAU participants completed the questionnaires. 
However at twelve weeks only sixty-five CCBT (57.5%) participants completed the primary 
outcome questionnaire (IBDQ) whereas seventy-eight TAU (90.7%) did so. Among CCBT 
completers, 24/29 (82.8%) completed the week twelve questionnaires. Drop out in the ITT 
CCBT for the week twelve questionnaires was significantly higher than in the TAU group 
(42.5% v. 9.3%, p = 0.048), whereas CCBT completers were no more likely to drop out than 
TAU participants (17.2% v. 9.3%, p = 0.87).  
Fifty-three CCBT (46.9%) and sixty-six TAU (76.7%) participants completed the IBDQ at 
six months. Among CCBT participants, 24/29 (82.8%) of completers did the questionnaires 
at six months. Drop out in the ITT CCBT group was again significantly higher than in the 
TAU group at the six month assessment point (53.1% v. 23.4%, p = 0.04), and again CCBT 
completers were no more likely to drop out than TAU participants (17.2% v. 23.4%, p 
=0.87). 
Outcomes and estimation 
Per-protocol outcomes 
Table 3 shows PP at twelve weeks and six months.  
Primary outcome measure 
PP CCBT completers had a greater increase in mean IBDQ scores than TAU participants (F = 
6.38, p = 0.01) at twelve weeks. 
Secondary outcome measures at twelve weeks 
SF-12 mental improved in CCBT completers versus TAU participants (F = 5.00, p = 0.03). 
All other outcomes were not significant (p > 0.05). 
Secondary outcome measures at six months 
At six months, religion (adaptive emotion-focused coping strategy) decreased more in TAU 
participants than CCBT completers (F = 4.39, p = 0.04), substance use (maladaptive coping 
strategy) decreased more in CCBT completers than TAU participants (F = 4.22, p = 0.04), 
and venting (maladaptive coping strategy) increased more in CCBT completers than TAU 
participants (F = 6.18, p = 0.02). All other outcomes were not significant at six months (p > 
0.05). 
Intention-to-treat 
Twelve weeks 
IBDQ (F = 0.59, p = 0.44) and SF-12 mental (F = 0.04, p = 0.83) did not significantly 
increase at twelve weeks. 
Six months 
IBDQ did not significantly increase (F = 0.46, p = 0.50). Substance use (F = 0.38, p = 0.54) 
did not significantly decrease and venting (F = 0.89, p = 0.35) did not significantly increase 
in CCBT versus TAU. Religion (F = 4.66, p = 0.03) decreased more in the TAU than CCBT 
group. 
Binary outcomes 
When the analysis was performed using IBDQ as a binary outcome, at twelve weeks, 45.8% 
of CCBT completers improved versus 24.4% of TAU participants and this was not significant 
(p = 0.07). No effects were found at six months for the PP population (41.7% versus 30.3%, p 
= 0.32). 
Ancillary analyses 
Completion of program 
Of the 113 people given access to the CCBT, 100 (88.5%) people downloaded at least one of 
the sixty-two resources. Twenty-nine (25.7%) completed the intervention. Univariate and 
multivariate analyses were carried out to determine predictors of study completion (Table 4): 
biological treatment and baseline depression significantly reduced the odds of completion 
while currently using prednisone and having an IBDQ score of above 160 increased the odds 
of completion. A multivariate model with biological treatment, baseline depression, and 
IBDQ score of above 160 was performed. In this model, none of the predictors were 
significant. 
Patient perceptions of the program 
Forty participants (22 completers) completed the questionnaires about their perceptions of the 
program (35.4%). The majority enjoyed the program (74%), felt it had relevance (87%), felt 
it improved their understanding of IBD (80%), felt it improved their physical and/or mental 
health (74%), and would recommend it to others with gastrointestinal disorders (80%). 
  
Discussion 
The primary aim of this study was to determine if CCBT significantly increases IBDQ scores 
in CCBT completers compared with TAU at twelve weeks after baseline. The primary 
hypothesis was supported in PP analyses although change in IBDQ scores did not differ 
between the groups in ITT analyses. The clinical significance of this is that those who 
complete at least 50% of the CCBT have an improvement of HRQOL. At twelve weeks, the 
mean SF-12 mental score increased more in CCBT completers than TAU participants. At six 
months, religion decreased in TAU compared to CCBT completers, substance use decreased 
in CCBT completers compared to TAU participants, and venting increased in CCBT 
completers compared to TAU participants. Only religion change scores remained significant 
in ITT analyses. 
The predictors of non-completion of CCBT were biological treatment (i.e. infliximab or 
adalimumab), depression, low IBDQ score, or not using prednisone at baseline. Generally, 
patients with more severe depression at baseline have a less favorable response to 
psychotherapy 
50, 51
 and there is poor adherence with medication among psychologically 
distressed people with IBD 
52-54
. Moreover, an IBS study reported that HRQOL was more 
impaired in dropouts than treatment completers 
55
, which is similar to what was found in this 
study. Severe disease (as indicated by low IBDQ scores) predicted dropout in this study and 
so it is consistent that those on biological treatment dropped out more because biological 
treatment is given to those with more severe and refractory disease
56
. On the other hand, the 
phenomenon of those on prednisone at baseline being less likely to drop out is more difficult 
to explain. Of note was that a relatively small percentage of the total sample was on 
biological treatment and prednisone and the mean dose of prednisone was low. 
The CCBT did not improve social functioning, perceived stress, or IBD symptoms. 
Nevertheless, most people who completed the acceptability questionnaire reported that the 
CCBT was enjoyable, relevant, improved understanding of IBD, improved physical and/or 
mental health, and would recommend the program to other people with IBD or other 
gastrointestinal disorders. Also, the open-ended qualitative answers were generally positive 
about the CCBT. 
Implications 
Overall, the findings were modest although promising in the short term among those who 
completed the CCBT. There is an unfortunate paradox with the prediction of completion of 
the CCBT: those who may benefit most from CCBT, namely those who experience 
psychological distress, are less likely to complete the intervention. Given that the effect of 
depression was not significant in the multivariate model (once baseline IBDQ scores and 
biological use were controlled for) suggests that the effect of depression is confounded by 
disease severity. Therefore, treating the disease itself is probably one of the most effective 
ways of treating the psychiatric morbidity associated with IBD. 
Some participants reported positive benefits from the CCBT, including an increase in their 
knowledge of their disease. There were no reported harms from this cheap intervention and 
so it is possible this program can be made available to many IBD patients via Crohn’s and 
Colitis websites in North America, Australasia, and Europe. At the very least, it provides a 
good basis for providing constructive information to IBD patients. 
Limitations and future directions 
There was no sham treatment and so participants were not blinded to whether they were 
receiving the treatment or not. Blinding was not seen as practical or worthwhile because the 
main aim was to see if the CCBT is better than the status quo. Blinding would not have 
improved the results in favor of the CCBT. 
This study did not reach the numbers calculated in the power calculation. Nevertheless, 199 
randomized participants is a significant number in a study of this nature and this is one of the 
largest CCBT studies in physically ill patients to date 
21
. 
The low adherence was of concern. Part of the reason for the modest adherence in the present 
study may have been that the website used was not as modern and user-friendly as other 
similar websites, such as one for depression 
57
. Nevertheless, it is common for CCBT studies 
to have high dropout rates, especially when there is no therapist contact 
58, 59
. For example, 
arguably the strongest RCT ever performed in CCBT for chronic physical illnesses was in 
patients with diabetes and reported only fifty-three out of 125 (42.4%) CCBT participants 
completed all sessions 
60
. Indeed, the participants in the present study anecdotally reported 
the CCBT was demanding and time consuming and it has been reported in a systematic 
review that dropout is more common as treatment length increases 
61
. Overall, attempts can 
be made to improve adherence through more human contact, less sessions, or a better 
website, but it is also possible modest adherence may be inevitable in CCBT studies 
irrespective of the quality of the website or therapist contact. Furthermore, increased human 
contact would decrease cost-effectiveness and the intervention in this study is already average 
in length in the context of CCBT studies 
21
. 
The high dropout, which is commonplace in such studies as this one 
23
, has an important 
implication: the PP analyses were highly susceptible to self-selection biases. Nevertheless, 
ITT analyses were performed in an attempt to detect treatment effects not caused by self-
selection. It cannot be expected that participants who do not utilize the materials of the CCBT 
can gain any benefits and so the PP analyses were acceptable in this context. Again, future 
research should focus on increasing treatment adherence. 
There was an initial improvement in IBDQ scores among CCBT completers but these 
positive effects were not maintained at six months. If there are no long terms gains from the 
CCBT, the CCBT may not be of use beyond the time at which the participants participate in 
it. Future research needs to attempt to address this through offering “booster” sessions of 
CCBT after it is completed. For example, booster sessions may improve long term outcomes 
in conventional CBT for depression 
62, 63
; future studies should explore this possibility in the 
context of CCBT for IBD participants. 
The amount of time since diagnosis was not recorded. This is problematic because perhaps 
newer diagnoses are more likely to complete or benefit from CCBT. Future research should 
record the time since diagnosis of each patient in the CCBT study. 
Finally, it was unknown whether some patients began psychiatric treatments of a medical or 
psychosocial nature outside the boundaries of the study. Future studies should ask the 
participants at twelve weeks and six months if they have started taking a new psychiatric 
medication or attending psychotherapy outside of the prescribed CCBT in the study since the 
study began. 
Conclusions 
This study aimed to improve the HRQOL of people who participate in a CCBT program. 
There were some improvements in IBDQ scores at twelve weeks after baseline but these were 
not maintained at six months. The high dropout rate from the CCBT group was of concern 
and future research should aim to improve adherence rates. Nevertheless, the CCBT helped 
some participants to better understand their IBD. Therefore, this type of intervention should 
be further tested in subgroups which may benefit and considered further by patient 
organizations as a means of educating their constituents. 
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Figure 1: Participant flow diagram 
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Table 1: TAU and CCBT participants’ demographics at baselinea 
Variable 
TAU
b
 (n
c
=86) 
n (%) 
CCBT
d
 
(n=113) 
n (%) 
Age
e
 39. 6 (11.8) 38.3 (12.8) 
Male Sex 33 (38.4) 38 (33.6) 
Diagnosis CD
f
 62 (72.1) 75 (66.4) 
UC
g
 20 (23.3) 34 (30.1) 
IBD-U
h
 4 (4.7) 4 (3.5) 
New Zealand born 69 (80.2) 93 (82.3) 
Ethnic group NZ European (solely) 75 (87.2) 100 (88.5) 
Other ethnicity 11 (12.8) 13 (11.5) 
Marital status Married, de Facto, engaged or civil 
union 
41 (47.7) 51 (45.1) 
Single 32 (37.2) 46 (40.7) 
Divorced, bereaved, or separated 12 (14.0) 14 (12.4) 
Not specified 1 (1.2) 2 (1.8) 
Highest Education Tertiary 31 (36.0) 50 (44.2) 
High School 41 (47.7) 50 (44.2) 
No high school, other or not specified 14 (16.3) 13 (11.5) 
Employment Full time work 44 (51.2) 64 (56.6) 
Part time work 22 (25.6) 30 (26.5) 
Full time study 3 (3.5) 11 (9.7) 
Part time study 5 (5.8) 6 (5.3) 
Beneficiary (any) 7 (8.1) 10 (8.8) 
Smoking status Current 13 (15.1) 11 (9.7) 
Former 30 (34.9) 35 (31.0) 
Never or decline to answer 43 (50.0) 67 (59.3) 
Previous surgery 26 (30.2) 28 (24.8) 
“j-pouch” surgery 0 (0.0) 1 (0.9) 
IBD
i
 Medication at baseline   
Pentasa 42 (48.8) 45 (39.8) 
Azathioprine or mercaptopurine 35 (40.7) 45 (39.8) 
Methotrexate 4 (4.7) 11 (9.7) 
Biological 15 (17.4) 21 (18.6) 
Asacol 8 (9.3) 10 (8.8) 
Colifoam 5 (5.8) 4 (3.5) 
Prednisone 9 (10.5) 9 (8.0) 
None  3 (3.5) 9 (8.0) 
Other 6 (7.0) 7 (6.2) 
Average prednisone dose/day (SD
j
) in mg 1.6 (5.8) 2.1 (9.1) 
a
 Percentages included for discrete data and standard deviations for continuous data. Continuous data includes 
age and average prednisone dose; 
b
 TAU= treatment as usual ;
c
 n= number in group; 
d
 CCBT=computerised 
cognitive behavioural therapy; 
e
 Age obtained for 111 CCBT and 82 TAU (6 missing) ;
f
 CD= Crohn’s disease ;g 
UC= ulcerative colitis; 
h
 inflammatory bowel disease-unspecified ;
i
 IBD=inflammatory bowel disease; 
j
 
SD=standard deviation.. 
Table 2: ITT CCBT and TAU participants’ questionnaire scores at baseline 
Questionnaire subscale n
a
 TAU
b
 (n=86) 
CCBT
c
 
(n=113) 
IBDQ
d
 199 160.5 (35.7) 163.6 (32.3) 
SF-12
e
 Mental 198 44.4 (12.00) 45.2 (10.1) 
SF-12 Physical 198 43.5 (9.9) 47.4 (8.9) 
HADS
f
-Anxiety 199 6.9 (4.1) 7.0 (4.1) 
HADS-Depression 199 4.9 (4.4) 4.6 (3.5) 
EPQ-BV
g
 Neuroticism 196 28.3 (9.4) 29.1 (10.5) 
SCCAI (UC and IBD-U)
h
 61 2.2 (2.3) 2.3 (2.4) 
HBI (CD)
i
 135 4.5 (4. 5) 3.6 (4.00) 
SFQ
j
 190 6.7 (3.7) 5.8 (3.6) 
PSS-10
k
 196 17.6 (7.1) 16.6 (7.4) 
Brief COPE
l
-adaptive problem focused TOTAL 192 13.4 (4.9) 12.7 (4.7) 
Active coping 195 4.8 (1.9) 4.8 (1.9) 
Use of instrument support 194 3.9 (1.9) 3.6 (1.7) 
Planning 193 4.6 (2.0) 4.3 (1.8) 
Brief COPE-adaptive emotion focused TOTAL 189 21.3 (5.7) 20.6 (5.8) 
Use of emotional support 195 4.1 (1.8) 4.0 (1.9) 
Positive reframing 193 4.2 (2.0) 3.8 (1.9) 
Humour 193 3.8 (1.7) 4.0 (2.0) 
Acceptance 195 6.2 (1.8) 6.2 (1.7) 
Religion 193 3. 0 (1.8) 2.7 (1.4) 
Brief COPE-Maladaptive maladaptive TOTAL 192 19.0 (6.0) 18.2 (5.0) 
Self-distraction 194 4.4 (2.0) 4.2 (1.8) 
Denial 196 2.6 (1.3) 2.5 (1.1) 
Substance use 195 2.7 (1.4) 2.6 (1.3) 
Behavioural disengagement 194 2.8 (1.2) 2.7 (1.2) 
Venting 194 3.4 (1.3) 3.3 (1.4) 
Self-blame 194 3.2 (1.6) 3.0 (1.1) 
a
 n=sample size; 
b
 TAU=treatment as usual; 
c
 CCBT=computerized cognitive behavioural therapy; 
d
 
IBDQ=Inflammatory Bowel Disease Questionnaire; 
e 
SF-12= Short Form 12; 
f
 HADS= Hospital Anxiety and 
Depression; 
g
 EPQ-BV=Eysenck Personality Questionnaire- Brief Version; 
h
 Simple Clinical Colitis Activity 
Index did not include extraintestinal manifestations; 
i
 Harvey-Bradshaw Index did not include complications or 
abdominal masses; 
j
 SFQ=Social Functioning Questionnaire; 
k 
PSS-10= Perceived Stress Scale; 
l
 Brief COPE= 
Brief Coping Operations Preference Enquiry 
Table 3: Per-protocol outcomes at 12 weeks and 6 months 
Variable 
Mean (and 
standard 
deviation) of 
change score of 
TAU
a
 at 12 
weeks 
Mean (and 
standard 
deviation) of 
change score of 
CCBT 
completers at 
12 weeks 
Mixed effects F 
value and p-
value at 12 
weeks 
Mean (and 
standard 
deviation) of 
change score of 
TAU at 6 
months 
Mean (and 
standard 
deviation) of 
change score of 
CCBT 
completers at 6 
months 
Mixed effects F 
value and p-
value at 6 
months 
IBDQ
b
 6.63 (25.21) 15.39 (22.97) 6.4, 0.01 11.74 (29.52) 12.64 (26.93) 1.0, 0.32 
SF-12
c
 Mental 2.57 (8.40) 5.61 (9.32) 5.0, 0.03 0.91 (9.77) 2.62 (12.72) 1.0, 0.31 
SF-12 Physical 2.52 (7.50) 3.22 (9.19) 1.6, 0.20 3.73 (8.87) 3.58 (9.30) 0.4, 0.54 
HADS
d
-Anxiety -1.08 (2.60) -1.07 (2.51) 0.2, 0.69 -0.66 (2.96) -1.63 (3.37) 1.8, 0.18 
HADS-Depression -0.86 (2.74) -1.33 (2.24) 2.2, 0.14 -0.51 (3.12) -0.48 (2.68) 0.0, 0.89 
SCCAI
e
 (UC
f
 and IBD-U
g
) -0.05 (1.90) -1.73 (4.82) 1.2, 0.27 -0.44 (1.54) -1.82 (2. 75) 1.7, 0.21 
HBI
h
 (CD) -0.68 (3.50) -0.69 (3.04) 1.1, 0.29 -1.60 (4.70) -0.42 (3.96) 0.4, 0.54 
SFQ
i
 -0.86 (2.23) -0.18 (2.60) 0.5, 0.48 -0.76 (2.87) -0.03 (2.71) 0.3, 0.58 
PSS-10
j
 -1.49 (5.61) -1.81 (6.21) 1.2, 0.27 1.05 (7.12) 1.51 (7.89) 0.0, 0.88 
Problem focused coping 
TOTAL 
-1.01 (4.31) -0.64 (4.83) 0.2, 0.64 -2.07 (4.14) -2.52 (3.31) 0.10, 0.82 
Active coping -0.19 (1.85) -0.30 (2.18) 0.0, 0.92 -0.72 (1.88) -0.88 (1.51) 0.5, 0.49 
Use of instrumental support -0.51 (1.73) -0.33 (1.76) 0.0, 0.86 -0.55 (1.72) -0.75 (1.39) 0.4, 0.51 
Planning -0.31 (1.80) 0.00 (1.69) 0.7, 0.41 -0.79 (1.67) -0.87 (1.60) 0.1, 0.77 
Emotion focused coping 
TOTAL 
-1.49 (4.31) -0.05 (5.58) 0.3, 0.59 -3.60 (4.54) -1.32 (4.32) 2.5, 0.12 
Use of emotional support -0.37 (1.43) -0.09 (1.12) 0.2, 0.69 -0.49 (1.32) -0.26 (0.96) 0.0, 0.92 
Positive reframing -0.29 (1.74) 0.13 (1.79) 0.1, 0.73 -0.61 (1.61) 0.17 (1.19) 1.9, 0.17 
Humour -0.17 (1.57) -0.33 (1.49) 0.2, 0.68 -0.34 (1.26) -0.38 (1.24) 0.0, 0.98 
Acceptance -0.47 (1.89) -0.13 (1.65) 0.6, 0.43 -1.39 (1.91) -0.82 (1.71) 0.5, 0.47 
Religion -0.09 (0.85) 0.21 (1.25) 1.9, 0.17 -0.55 (1.49) 0.00 (1.25) 4.4, 0.04 
Maladaptive coping TOTAL -1.99 (4.14) -1.17 (2.96) 0.0, 1.00 -2.00 (3.67) -0.36 (3.86) 1.3, 0.26 
Self-distraction -0.58 (1.74) -0.25 (1.33) 0.1, 0.79 -0.68 (1.82) -0.83 (1.09) 0.0, 0.85 
Variable 
Mean (and 
standard 
deviation) of 
change score of 
TAU
a
 at 12 
weeks 
Mean (and 
standard 
deviation) of 
change score of 
CCBT 
completers at 
12 weeks 
Mixed effects F 
value and p-
value at 12 
weeks 
Mean (and 
standard 
deviation) of 
change score of 
TAU at 6 
months 
Mean (and 
standard 
deviation) of 
change score of 
CCBT 
completers at 6 
months 
Mixed effects F 
value and p-
value at 6 
months 
Denial -0.32 (0.83) -0.08 (0.72) 0.5, 0.48 -0.18 (0.90) -0.95 (2.32) 0.0, 0.98 
Substance use -0.06 (1.13) -0.29 (0.75) 1.0, 0.32 -0.10 (0.99) -0.43 (2.41) 4.2, 0.04 
Behavioural disengagement -0.38 (1.02) -0.39 (0.84) 1.5, 0.23 -0.39 (1.13) -0.22 (2.00) 0.0, 0.91 
Venting -0.27 (1.26) 0.21 (1.18) 1.2, 0.28 -0.17 (1.12) 0.74 (2.67) 6.2, 0.02 
Self-blame -0.35 (1.28) -0.21 (1.47) 0.0, 0.85 -0.43 (1.17) -0.83 (1.09) 1.3, 0.25 
a
 TAU=treatment as usual; 
b
 IBDQ= Inflammatory Bowel Disease Questionnaire; 
c
 SF-12= Short Form 12; 
d
 HADS= Hospital Anxiety and Depression Scale; 
e
 Simple 
Clinical Colitis Activity Index; 
f
 UC=ulcerative colitis; 
g
 IBD-U=inflammatory bowel disease-unspecified; 
h
 HBI= Harvey-Bradshaw Index; 
i
 SFQ=Social Functioning 
Questionnaire; 
j
PSS-10= Perceived Stress Scale; 
Table 4: Predictors of completion of program
a
 
  Unadjusted Adjusted
b
 
Predictor N
c
 OR
d
 95% CI
e
 OR 95% CI 
Aged 40 or older
f
 52 1.61 0.69-3.76   
Male 38 1.29 0.54-3.11   
In a relationship
g
 51 1.03 0.44-2.42   
Tertiary educated 50 1.24 0.53-2.90   
CD (not UC or IBD-U) 75 0.64 0.27-1.52   
New Zealand born
h
 93 0.97 0.32-2.99   
New Zealand European 100 1.17 0.30-4.59   
Full time employment 64 0.77 0.33-1.79   
Full time study 11 0.62 0.13-3.04   
Beneficiary (any kind) 10 0.30 0.04-2.46   
Current smoker 11 1.76 0.48-6.51   
Pentasa
i
 45 2.29 0.97-5.42   
Azathiopurine or 
mercaptopurine
i
 
45 0.59 0.24-1.44   
Methotrexate
i
 11 0.61 0.12-3.00   
Biological
i
 21 0.11 0.01-0.88 0.15 0.02-1.17 
Asacol
i
 10 2.05 0.54-7.87   
Colifoam
i
 4 0.95 0.10-9.54   
Prednisone
i
 9 4.12 1.02-16.55   
Baseline IBDQ
j
 above 160 62 2.75 1.10-6.91 2.02 0.77-5.30 
Baseline SF-12 mental above 
50
k
 
39 0.64 0.25-1.62   
Baseline SF-12 physical 
above 50
k
 
53 0.60 0.25-1.42   
Baseline anxiety caseness
l
 43 0.81 0.34-1.97   
Baseline depression caseness
l
 25 0.20 0.04-0.89 0.29 0.06-1.38 
Baseline neuroticism above 
30 
44 1.08 0.46-2.56   
Baseline PSS-10 above 17
m
 52 0.88 0.37-2.05   
Poor social functioning at 
baseline
n
 
18 0.30 0.06-1.39   
Maladaptive coping at 
baseline above 17
o
 
51 0.53 0.22-1.29   
Emotion-focused coping at 
baseline above 17
p
 
75 0.74 0.29-1.89   
Problem-focused coping at 
baseline above 17
o
 
21 1.18 0.41-3.42   
a
 Completion defined as downloading 50% of available resources and irrespective of whether 12 week 
questionnaires were completed or not; 
b
 All significant variables from univariate analyses included in 
multivariate analysis except for prednisone which had a small sample size. Sample size 112 for multivariate 
analysis; 
c
 number of people out of 113 in this category ; 
d
 OR= odds ratio; 
e
 CI= confidence interval; 
f
 112 ages 
available; 
g
 111 relationship statuses available; 
h
 112 places of birth available;
i
 112 answers available for 
medications (one declined to answer medication questions); 
j
 IBDQ=Inflammatory Bowel Disease 
Questionnaire; 
k
 112 cases available for SF-12; 
l
 Caseness defined as 8 or more on HADS subscale. 112 
available cases for anxiety and 111 for depression; 
m
 110 PSS-10 scores available; 
n
 Caseness defined as 10 or 
more on SFQ; 
o
 108 precontemplation, preparation, action, maladaptive coping, and problem-focused coping 
scores available; 
p
 105 emotion-focused coping scores available 
Supplementary Table 1: CCBT topics and resources 
Week Resource Resource type Length/Burden Description of resource 
ONE Introduction and 
appropriate goal 
setting 
   
 Week 1 Resource 
1: Introduction to 
the program 
pdf 4 pages Introduces program in general terms; introduces study co-
ordinator; defines cognitive behavioural therapy; and states 
the aims of the study. 
 Week 1 Resource 
2: Appropriate goal 
setting 
Pdf/PowerPoint 5 pages/10 
slides 
Says why goal-setting is important; says what the important 
characteristics of goal setting are; and challenges 
participants to set goals. 
 Goal setting Q&A 2 questions Asks questions about short terms and long term goals. 
 Week 1 Resource 
3: Recognising 
stress and symptom 
checklist 
pdf 2 pages Teaches person how to recognise stress. 
 Recognising your 
stress 
Q&A 3 questions Asks 3 questions about stress, the significance of it, and 
what their strategies are for managing stress. 
 Information video 
about IBD 
Video 18 minutes Clinical psychologist interviewing gastroenterologist. 
Available at 
https://www.youtube.com/watch?t=297&v=nAlJVHXYCpw 
TWO Relaxation 
techniques 
   
 Revision of week 1 pdf 1 page Reiterates what was said in session 1. 
 Week 2 Resource 
1: Stress 
management 
Pdf/PowerPoint 2 pages/8 slides Talks about the important of stress and the fight or flight 
response. 
 Stress Awareness 
Diary  
pdf 1 page A diary with the time, the stressful event, and the physical 
symptom described. 
 Week 2 Resource 
2: Relaxation 
pdf 1 page Alludes to body awareness, progressive muscle relaxation, 
deep diaphragmatic breathing, and the clenched fist 
Week Resource Resource type Length/Burden Description of resource 
techniques technique which are below. 
 Body Awareness Sound file 9 minutes 
All sound files available at the bottom of the following 
webpage: http://www.tameyourgut.com/#!week-2/cepq 
 Progressive muscle 
relaxation 
Sound file 18 minutes 
 Clenched Fist Brief 
Relaxation 
Sound file 8 minutes 
 Deep 
Diaphragmatic 
Breathing 
Sound file 9 minutes 
 Discuss which 
stress management 
techniques you find 
useful  
Q&A 1 question 
Asked to discuss which stress management techniques they 
find most useful. 
 Week 2 Resource 
3: Worry and sleep 
pdf 4 pages Teaches about sleep hygiene. 
 Information video 
about IBD: part 2  
Video 20 minutes Available at 
https://www.youtube.com/watch?v=XrnAHwaEPv8 
THREE Thoughts and 
feelings about IBD 
(part 1) 
   
 Revision of Week 2 pdf 1 page Reiterates what was said in session 2. 
 Week 3 Resource 
1:Thoughts and 
feelings about IBD 
pdf 8 pages 
Talks about thoughts feelings and behaviours and cognitive 
distortions that can lead to bad feelings and behaviours. 
 Week 3 Resource 
2: The Downward 
Arrow Technique 
pdf 2 pages 
Teaches how to use the Downward Arrow Technique. 
 Recognising 
cognitive 
distortions 
Q&A 3 questions 
Asks to give examples of overgeneralisation, negative 
filtering, and black-and-white thinking. 
 Extra information Video 14 minutes Available at (in one video) 
Week Resource Resource type Length/Burden Description of resource 
video-week 3 part 1 https://www.youtube.com/watch?v=z_kWDMib3As 
 Extra information 
video-week 3 part 2 
Video 13 minutes 
FOUR Thoughts and 
feelings about IBD 
(part 2) 
   
 Revision of week 3 pdf 1 page Reiterates what was said in session 3. 
 Week 4 Resource 
1: Appraisal and 
mood 
Pdf/PowerPoint 4 pages/6 slides Teaches how to link thoughts, feelings, and behaviours. 
 Week 4 Resource 
2: Cognitive 
restructuring 
pdf 6 pages Teaches how to replace cognitive distortions with more 
helpful ways of thinking. 
 Week 4 Resource 
3: Challenging 
negative automatic 
thoughts  
pdf 9 pages Teaches how to challenge negative automatic thoughts using 
the A, B, C, D, E approach. 
 A note on positive 
thinking 
pdf 1 page Talks about not having unconditional positive thinking but 
rather “realistic, balanced, and flexible” thinking. 
FIVE Avoiding 
avoidance 
   
 Cognitive 
distortions: 
Revision of weeks 
3 and 4. 
PowerPoint 10 slides Uses some cartoon pictures to demonstrate cognitive 
distortions that were talked about in sessions three and four. 
 Week 5 Resource 
1: Confronting 
avoidance 
pdf 2 pages Talks about avoidance in IBD patients and how to confront 
it. 
 Week 5 Resource 
2: Desensitization 
pdf 5 pages Teaches systematic desensitisation using an anxiety 
hierarchy. 
 Exposure Q&A 4 question Asks four questions about what fear a person would like to 
Week Resource Resource type Length/Burden Description of resource 
Hierarchy overcome, and what low, medium, and high exposures to 
this fear are. 
 Hierarchy 
Cards(for imagery 
exposure in 
"confronting 
avoidance above 
pdf 1 page A simple resource people can print out to make an exposure 
hierarchy using cards. 
 Imaginal Exposure 
Instructions 
pdf 2 pages How to make an imaginal exposure hierarchy and practice 
imagery desensitisation. 
 Troubleshooting 
exposure 
pdf 1 page Talks about some problems that can be encountered during  
 systematic desensitization 
SIX Coping strategies 
and diet 
   
 Revision of week 5 pdf 1 page Reiterates what was said in session 5. 
 Week 6 Resource 
1: Coping 
strategies 
Pdf/PowerPoint 5 pages/8 slides Defines coping and separates coping into problem- versus 
emotion- focused coping. 
 Coping resources Q&A 5 questions Asks questions about the coping strategies for 
uncontrollable and controllable stressors. 
 Week 6 Resource 
2: Diet and IBD 
(emphasis on 
FODMAPS) 
PowerPoint 30 slides 
Talks about how low FODMAP diets can have a role in IBD 
management. 
 Dietary factors in 
IBD 
Discussion 
forum 
4 discussion 
topics 
Asks participants to discuss dietary triggers, dietary 
symptom relievers, whether they have head of the low 
FODMAP diet, and if they would consider doing the low 
FODMAP diet. 
 OPTIONAL extra 
video: Dietician Dr 
Sheppard video 1 
Video 31 minutes 
Available at (in one video) 
https://www.youtube.com/watch?v=OPTCKWkwi2Y 
 OPTIONAL extra Video 29 minutes 
Week Resource Resource type Length/Burden Description of resource 
video: Dietician Dr 
Sheppard video 2 
SEVEN Relationships and 
effective 
communication 
   
 Revision of week 6 pdf 1 page Reiterates what was said in session 6. 
 This supplements 
and summarises, 
but does not 
replace, week 7 
resources 1, 2, 3, 4, 
and 5 
PowerPoint 17 slides 
Collectively, resources 1, 2, 3, 4, and 5 talk about types of 
social support, how to communicate effectively about IBD, 
how to manage arguments, what assertiveness, and how to 
be more assertive. 
 Week 7 Resource 
1: Types of social 
support  
pdf 2 pages 
 Week 7 Resource 
2: Effective 
communication  
pdf 3 pages 
 Week 7 Resource 
3: When things get 
heated  
pdf 2 pages 
 Week 7 Resource 
4: Assertiveness  
pdf 1 page 
 How Assertive Are 
You?  
pdf 1 page 
 Week 7 Resource 
5: Being more 
assertive and 
learning how to say 
“no” 
pdf 2 pages 
EIGHT Attention    
Week Resource Resource type Length/Burden Description of resource 
distraction 
techniques and 
looking to the 
future. 
 Revision of week 7 pdf 1 page Reiterates what was said in session 7. 
 Week 8 Resource 
1: Attention and 
distraction in pain 
management sound 
file 
Sound file 5 minutes This sound byte talks about attention and distraction in pain 
management 
 Week 8 Resource 
2: Relaxation, 
focussing, 
grounding exercise 
sound file 
Sound file 30 minutes This sound byte is a grounding exercise sound file 
 Week 8 Resource 
3: Attention and 
distraction 
techniques  
pdf 2 pages This is about taking attention away from the negative 
aspects of IBD, such as through imagining a “pain free 
room, ” paying attention to parts of the body that are not in 
pain, and relocating thoughts. 
 Week 8 Resource 
4: Other ways for 
managing pain.  
pdf 1 page Talks about other ways of managing pain, such as through 
watching a comedy show or movie, listening to music, or 
exercise.  
 Pain management Discussion 
forum 
1 broad topic People asked to discuss the methods people use to cope with 
the pain. 
 Wrapping up the 
program 
PowerPoint 6 slides Talks about what has been learnt over the 8 sessions and 
how these can be maintained over the long term. 
 Healthy me 
worksheet 
pdf 1 page This worksheet is to assist people in coming up with 
methods for becoming healthier (e.g., exercise, relaxation, 
pleasant activities, and having social support). 
 
Supplementary Table 2: Assessment timing 
 
Screening Baseline 12 weeks 
6 
months 
Screening criteria and consent x 
   
Demographics x x 
  
IBDQ
a
 (32 questions) 
 
x x x 
SF-12
b
 (12 questions)  x x x 
HADS
c
 (14 questions)  x x x 
Brief COPE (28 questions)  x x x 
SFQ
d
 (8 questions)  x x x 
HBI
e
 (3 questions) 
 
x x x 
SCCAI
f
 (5 questions) 
 
x x x 
PSS-10
g
 
 
x x x 
EPQ-BV-Neuroticism
h
 (12 questions)  x   
Patient perceptions of the program (10 
questions) 
  x  
a
 IBDQ=Inflammatory Bowel Disease Questionnaire; 
b
 SF-12=Short Form-12; 
c
 HADS= Hospital Anxiety and 
Depression Scale; 
d
 SFQ=Social Functioning Questionnaire; 
e
 HBI= Harvey-Bradshaw Index; 
f
 SCCAI= Simple 
Clinical Colitis Activity Index; 
g
 PSS-10= perceived stress questionnaire; 
h
 EPQ-BV-Neuroticism= Eysenck 
Personality Questionnaire-Brief Version neuroticism subscale 
 
